Creative Biolabs provides you with our toxicology-on-a-chip model, which can accurately control the local environment and simulate human organ function in vitro and is an advantageous weapon to solve the key issues of new drug development.
Our toxicology-on-a-chip model uses co-culture techniques that also have been widely to establish a microenvironment that is closer to the body and maintains cell functions. By establishing a nylon scaffold that allows a three-dimensional culture of non-parenchymal cells including Kupffer cells, stellate cells, sinusoidal endothelial cells, and bile duct endothelial cells, which can maintain the specific functions of the long-term, form bile duct-like structures, and respond to inflammatory stimuli as well as simulating the toxic response of a whole organ to drug candidates.
Fig 1. A liver chip system for drug toxicity testing. (Cong, 2020)
Selecting biomarkers for effective drug toxicity testing is a critical step. Creative Biolabs provides you with an overview of the toxic biomarkers utilized in our toxicology-on-a-chip models.
Toxicity | Biomarker | Specification |
Hepatotoxicity |
ALT (alanine aminotransferase) AST (aspartate aminotransferase) |
Diagnostic marker of liver damage |
ALP (alkaline phosphatase) | Diagnostic marker of cholestatic injury | |
K18 (keratin-18) | Early detection biomarker | |
GST-α (glutathione S-transferase α) | Early detection biomarker | |
CYP (cytochrome P450) | Metabolic ability biomarker | |
miRNA-122, miRNA-192 | Genomic markers | |
CDH-5 (cadherin-5) | Proteomics biomarker | |
Nephrotoxicity | GFR (glomerular filtration rate) | Diagnostic marker of renal function |
SCr levels and urine output | Diagnostic marker of AKI (acute kidney injury) | |
KIM-1 (kidney injury molecule-1) | Early detection biomarker | |
NAG (N-acetyl-β-glucosaminidase) | Early detection biomarker | |
NGAL (neutrophil gelatinase-associated lipocalin) | Early detection biomarker | |
CYs C (cystatin C) | Early detection biomarker | |
TEER (transendothelial resistance) | Biomarker of barrier functions | |
miRNAs | Genomic markers | |
Cardiotoxicity |
LVDP (left ventricular formation pressure) LVSP (left ventricular systolic pressure) |
Diagnostic marker of myocardial injury |
miR-146a, miR-1, miR-133, miR-208, miR-499 | Genomic markers | |
beating frequency, systolic stress, field potential | Mechanical markers | |
TEER | Biomarker of barrier functions | |
Neurotoxicity | miR-425-p, miR-21, miR-93, miR-191, miR-499, miR-328, miR-362-3p, miR-451, miR-486a | Genomic markers |
SP, sCD40L, TIMP-1, MDA, CK-18 | Early detection biomarkers | |
Other toxicities | CD64, C-reactive protein | Biomarker of small/large intestine |
NOS isoenzymes | Breath biomarkers | |
HO (heme oxygenase) | Biomarker of upper respiratory tract viral infections | |
CYP (cytochrome P450) H2O2 |
Biomarker of pulmonary diseases | |
TEER | Biomarker of barrier functions |
Table 1. Some common biomarkers for drug toxicity evaluation. (Cong, 2020)
Drug toxicity is one of the major reasons for post-market drug withdrawal; therefore, it is crucial to perform preclinical toxicity testing on candidate drugs. Toxicology-on-a-chip model of Creative Biolabs with the technology to achieve rapid high-throughput production of organ chip tissue will greatly reduce your production costs and operational difficulties.
In addition to the toxicology-on-a-chip model, we offer a diverse range of alternative models that might be of interest to you:
With years of experience in drug discovery, a group of specialists at Creative Biolabs possesses a keen insight into diverse research demands from our worldwide clients. Beyond delivering premium disease-on-a-chip models, we are dedicated to propelling your research pursuits by presenting a diverse and comprehensive range of 3D biology-based services. We warmly invite you to connect with us to expedite the achievements of your project.
Reference